Preliminary results of KRYSTAL-1 showed that patients with advanced NSCLC and co-mutations of KRAS-G12C and STK11 had an ORR of 64% (9/14) across the pooled cohorts of phase I/Ib and II studies. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.